Emerging Pharmaco-Therapeutic Role of Metformin in Prediabetes and Other Diverse Conditions
Abstract
No abstract
References
1. Unwin N, Whiting D, Guariguata L, Ghyoot G, Gan D (Eds). The IDF Diabetes Atlas, 5th edition. Brussels, Belgium: International Diabetes Federation; 2011. pp.7-12.
2. Indian Heart Association Why South Asians Facts Web. 30 April 2015.
4. Buysschaert M, Bergman M. Definition of prediabetes. Med Clin North Am. 2011 Mar;95(2):289-97
5. Tirabanchasak S, Siripunthana S, Supornsilchai V, Wacharasindhu S, Sahakitrungruang T. Insulin dynamics and biochemical markers for predicting impaired glucose tolerance in obese Thai youth. J Pediatr Endocrinol Metab. 2015; May 29. pii: /j/jpem.ahead-ofprint/ jpem- 2014- 0273/jpem-2014-0273.xml.)
6. Nichols GA, Hillier TA, Brown JB “Progression from Newly Acquired Impaired Fasting Glusose to Type 2 Diabetes”. Diabetes Care. 2007; 30: 228–233.
7. Barr EL, Zimmet PZ, Welborn TA et al. “Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)”.Circulation. 2007; 116 : 151–7.
8. National Diabetes Statistics Report, 2014 (released June 10, 2014)
9. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007 ;125:217-30.
10. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA,Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 ; 346 :393-403.
11. Snehalatha C, Mary S, Joshi VV, Ramachandran A. Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diab Vasc Dis Res. 2008; 5:25-9.
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) The Lancet. 1998;352(9131):837-853.
13. Lily M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician. 2009; 55:363-9
14. Moin T, Li J, Duru OK, Ettner S, Turk N, Keckhafer A, Ho S, Mangione CM Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. Ann Intern Med. 2015; 162:542-8.
15.Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM,et al Initial choice of oral glucose- lowering medication for diabetes mellitus: a patient- centered comparative effectiveness study. JAMA Intern Med. 2014;174:1955-62.
16.Niafar M , Hai F, Porhomayon J, Nader ND . The role of metformin on vitamin B12 deficiency: a meta-analysis review. Intern Emerg Med. 2015;10:93-102.
17.Festa A, Hanley AJ, Tracy RP, D’Agostino R Jr, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation. 2003; 108:1822-30.
18.Dunaif A Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis Endocr Rev. 1997; 18:774-800.
19.Shringi MS, Vaidya RA, Gogate JV et al. Insulin Resistance in polycystic Ovary Syndrome- a study of 90 patients. Indian J Endocrinol Metab. 2003; 5; 19-21
20. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713-23.
21.Steven E. Shoelson, Jongsoon Lee, and Allison B. Goldfine Inflammation and insulin resistance. J Clin Invest. 2006; 116: 1793–1801.
22. Vaidya RA, Pandey SN and Vaidya AB Polycystic Ovary Syndrome: Is it a chronic inflammatory disease? ECAB Clinical Update Obstetrics and Gynecology. 2008;1:42-73
23. Khan IM, Dai Perrard XY, Brunner G, Lui H, Sparks LM, Smith SR. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes. (Lond). 2015 Jun 4. doi: 10.1038/ijo.2015.104
24. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008 19371-9
25. Xu H , Barnes GT., Yang Q , Tan G , Yang D , Chou CJ. Et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821–1830.
26. Chawla A, Nguyen KD. & Goh YPS. Macrophagemediated inflammation in metabolic disease. Nature Reviews Immunology. 2011; 11: 738-749
27. Mertia P, Agashe S, Rege N and Vaidya RA. Polycystic Ovary Syndrome and Leucocytosis. The Indian Practitioner. 2014. Vol.67 No.8: 483-5
28. Patade GR, Marita AR. Metformin: A Journey from countryside to the bedside. J Obes Metab Res. 2014;1:127-30.
29. Vasamsetti SB, Karnewar S, KanugulaAK, Raj A, Kumar JM and Kotamraju Metformin inhibits monocyte- to-macrophage differentiation via AMPK mediated inhibition of STAT3 activation: Potential role in atherosclerosis. Diabetes. 2014;64(6):2028-41.
30. Hattori Y, Hattori K, Hayashi T. Pleiotropic Benefits of Metformin: Macrophage Targeting Its Antiinflammatory Mechanisms. Diabetes. 2015 ;64:1907-9.
31. Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther. 2014 ;31:30-43.
32. Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015 Jun 9. pii: dmv025. [Epub ahead of print]
33. Saisho Y. Metformin and inflammation: Its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets. 2015 Mar 16. [Epub ahead of print]
2. Indian Heart Association Why South Asians Facts Web. 30 April 2015.
4. Buysschaert M, Bergman M. Definition of prediabetes. Med Clin North Am. 2011 Mar;95(2):289-97
5. Tirabanchasak S, Siripunthana S, Supornsilchai V, Wacharasindhu S, Sahakitrungruang T. Insulin dynamics and biochemical markers for predicting impaired glucose tolerance in obese Thai youth. J Pediatr Endocrinol Metab. 2015; May 29. pii: /j/jpem.ahead-ofprint/ jpem- 2014- 0273/jpem-2014-0273.xml.)
6. Nichols GA, Hillier TA, Brown JB “Progression from Newly Acquired Impaired Fasting Glusose to Type 2 Diabetes”. Diabetes Care. 2007; 30: 228–233.
7. Barr EL, Zimmet PZ, Welborn TA et al. “Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)”.Circulation. 2007; 116 : 151–7.
8. National Diabetes Statistics Report, 2014 (released June 10, 2014)
9. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007 ;125:217-30.
10. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA,Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 ; 346 :393-403.
11. Snehalatha C, Mary S, Joshi VV, Ramachandran A. Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diab Vasc Dis Res. 2008; 5:25-9.
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) The Lancet. 1998;352(9131):837-853.
13. Lily M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician. 2009; 55:363-9
14. Moin T, Li J, Duru OK, Ettner S, Turk N, Keckhafer A, Ho S, Mangione CM Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. Ann Intern Med. 2015; 162:542-8.
15.Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM,et al Initial choice of oral glucose- lowering medication for diabetes mellitus: a patient- centered comparative effectiveness study. JAMA Intern Med. 2014;174:1955-62.
16.Niafar M , Hai F, Porhomayon J, Nader ND . The role of metformin on vitamin B12 deficiency: a meta-analysis review. Intern Emerg Med. 2015;10:93-102.
17.Festa A, Hanley AJ, Tracy RP, D’Agostino R Jr, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation. 2003; 108:1822-30.
18.Dunaif A Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis Endocr Rev. 1997; 18:774-800.
19.Shringi MS, Vaidya RA, Gogate JV et al. Insulin Resistance in polycystic Ovary Syndrome- a study of 90 patients. Indian J Endocrinol Metab. 2003; 5; 19-21
20. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59:713-23.
21.Steven E. Shoelson, Jongsoon Lee, and Allison B. Goldfine Inflammation and insulin resistance. J Clin Invest. 2006; 116: 1793–1801.
22. Vaidya RA, Pandey SN and Vaidya AB Polycystic Ovary Syndrome: Is it a chronic inflammatory disease? ECAB Clinical Update Obstetrics and Gynecology. 2008;1:42-73
23. Khan IM, Dai Perrard XY, Brunner G, Lui H, Sparks LM, Smith SR. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes. (Lond). 2015 Jun 4. doi: 10.1038/ijo.2015.104
24. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008 19371-9
25. Xu H , Barnes GT., Yang Q , Tan G , Yang D , Chou CJ. Et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821–1830.
26. Chawla A, Nguyen KD. & Goh YPS. Macrophagemediated inflammation in metabolic disease. Nature Reviews Immunology. 2011; 11: 738-749
27. Mertia P, Agashe S, Rege N and Vaidya RA. Polycystic Ovary Syndrome and Leucocytosis. The Indian Practitioner. 2014. Vol.67 No.8: 483-5
28. Patade GR, Marita AR. Metformin: A Journey from countryside to the bedside. J Obes Metab Res. 2014;1:127-30.
29. Vasamsetti SB, Karnewar S, KanugulaAK, Raj A, Kumar JM and Kotamraju Metformin inhibits monocyte- to-macrophage differentiation via AMPK mediated inhibition of STAT3 activation: Potential role in atherosclerosis. Diabetes. 2014;64(6):2028-41.
30. Hattori Y, Hattori K, Hayashi T. Pleiotropic Benefits of Metformin: Macrophage Targeting Its Antiinflammatory Mechanisms. Diabetes. 2015 ;64:1907-9.
31. Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther. 2014 ;31:30-43.
32. Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015 Jun 9. pii: dmv025. [Epub ahead of print]
33. Saisho Y. Metformin and inflammation: Its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets. 2015 Mar 16. [Epub ahead of print]
Published
2019-08-13
How to Cite
Dr Ameya Joshi, Vaidya R. (2019). Emerging Pharmaco-Therapeutic Role of Metformin in Prediabetes and Other Diverse Conditions. The Indian Practitioner, 68(6), 80-84. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/608
Section
Review article
